AR046704A1 - Compuestos derivados de quinolina, composiciones de los mismos y metodos para la inhibicion de la selectina - Google Patents

Compuestos derivados de quinolina, composiciones de los mismos y metodos para la inhibicion de la selectina

Info

Publication number
AR046704A1
AR046704A1 ARP040104129A ARP040104129A AR046704A1 AR 046704 A1 AR046704 A1 AR 046704A1 AR P040104129 A ARP040104129 A AR P040104129A AR P040104129 A ARP040104129 A AR P040104129A AR 046704 A1 AR046704 A1 AR 046704A1
Authority
AR
Argentina
Prior art keywords
alkyl
arylalkyl
aryl
heterocycle
alkynyl
Prior art date
Application number
ARP040104129A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR046704A1 publication Critical patent/AR046704A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Compuestos que actúan como antagonistas de las proteínas de adhesión en mamíferos conocidas como selectinas. En algunas modalidades, se proveen los métodos de tratamiento de desórdenes mediados por la selectina. Reivindicación 1: Un compuesto que tiene la formula (1): o una sal farmacéuticamente aceptable del mismo; caracterizado porque: L es CO2H, un ester del mismo, o un ácido mimético farmacéuticamente aceptable; Y es O, (CR3R4)p o NR5; p es de 1 a 3; X es hidrógeno, OH, OR3, Oalquilo C1- 6, OC(=O) arilo, OC(=O) alquilo C1-6, OC(=O)O alquilo C1-6 o NR3R3; cada R1, R2, R3, R3' y R4 es independientemente hidrógeno, alquilo C1-6, perhaloalquilo C1-6, Oalquilo C1-6, Operhaloalquilo C1-6, halógeno, tioalquilo, CN, OH, SH, (CH2)nOSO3H, (CH2)nSO3H, (CH2)nCO2R6, OSO3R6, SO2R6, SO3R6, PO3R6R7, (CH2)nSO2NR8R9, (CH2)nC(=O)NR8R9, NR8R9, C(=O)R12 arilo, heterociclo, C(=O) arilo, C(=O) heterociclo, OC(=O) arilo, OC(=O) heterociclo, Oarilo, Oheterociclo, arilalquilo, C(=O) arilalquilo, OC(=O) arilalquilo, Oarilalquilo, alquenilo, alquinilo, o NHCOR8, en donde cualquiera de dichos alquilo, Oalquilo, arilo, heterociclo, C(=O) arilo, C(=O) hetericiclo, O-C(=O) arilo, O-C(=O) hetericiclo, O-arilo, O- heterociclo, arilalquilo, C(=O) arilalquilo, O-C(=O) arilalquilo, O-arilalquilo, alquenilo o alquinilo pueden opcionalmente ser sustituidos con hasta tres substituyentes iguales o distintos seleccionados del halógeno, alquilo C1-6, Oalquilo C1-6 y CN; cada R6 y R7 es seleccionado independientemente a partir del grupo que consiste en hidrógeno y alquilo C1-6 que es opcionalmente substituido con hasta tres substituyentes iguales o diferentes seleccionados a partir del OH, CF3, SH y halógeno; cada R5, R8 y R9 es seleccionado independientemente a partir del grupo que consiste en hidrógeno, alquilo C1-6, haloalquilo C1-6, tioalquilo, OH, (CH2)lOSO3H, (CH2)1SO3R10, (CH2)nCO2R10, SO3R10, PO3R10R11, (CH2)nSO2(CH2)nNR10R11, (CH2)nCONR10R11, COR10, arilo, heterociclo, C(=O) arilo, C(=O) hetericiclo, O-C(=O) arilo, O-C(=O) heterociclo, Oarilo, Oheterociclo, arilalquilo, C(=) arilalquilo, OC(=O) arilalquilo, Oarilalquilo, alquenilo, o alquinilo, en donde uno de dichos alquilo, arilo, heterociclo, arilo C(=O), hetericicloC(=O), OC(=O), OC(=O) hetericiclo, Oarilo, Oheterociclo, arilalquilo, C(=O)arilalquilo, OC(=O) arilalquilo, Oarilalquilo, alquenilo o alquinilo pueden estar opcionalmente substituidos con hasta tres substituyentes iguales o diferentes seleccionados de halógeno, alquilo C1-6, Oalquilo C1-6 y CN; cada n es un entero seleccionado independientemente de 0 a 6; cada 1 es un entero seleccionado independientemente de 1 a 6; cada R10 y R11 es seleccionado independientemente del grupo que consiste en hidrógeno y alquilo C1-6 que está opcionalmente substituido con hasta tres substituyentes iguales o diferentes seleccionados a partir de QH, CF3, SH y halógeno; cada R12 es independientemente hidrógeno, alquilo C1-6, perhaloalquilo C1-6, Oalquilo C1-6. Operhaloalquilo C1-6, tioalquilo OH, (CH2)1OSO3H, (CH2)1SO3H, (CH2)1CO2R6, (CH2)1SO2NR8R9, (CH2)1C(=O)NR8R9, NR8R9, alquenilo, alquinilo, o NHCOR8, en donde cualquiera de dichos alquilo, Oalquilo, alquenilo o alquinilo pueden ser substituidos opcionalmente con hasta tres subtituyentes iguales o diferentes seleccionados a partir de halógeno, alquilo C1-6, Oalquilo C1-6 y CN; y Z es arilo, arilalquilo, heteroarilo o heterociclo, en donde cada uno de dichos arilo, arilalquilo, heteroarilo y heterociclo es opcionalmente substituido.
ARP040104129A 2003-11-10 2004-11-09 Compuestos derivados de quinolina, composiciones de los mismos y metodos para la inhibicion de la selectina AR046704A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51895003P 2003-11-10 2003-11-10

Publications (1)

Publication Number Publication Date
AR046704A1 true AR046704A1 (es) 2005-12-21

Family

ID=34590327

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104129A AR046704A1 (es) 2003-11-10 2004-11-09 Compuestos derivados de quinolina, composiciones de los mismos y metodos para la inhibicion de la selectina

Country Status (21)

Country Link
US (2) US7465799B2 (es)
EP (1) EP1682511A2 (es)
JP (1) JP2007510742A (es)
KR (1) KR20060108666A (es)
CN (1) CN1902179A (es)
AR (1) AR046704A1 (es)
AU (1) AU2004288800A1 (es)
BR (1) BRPI0416357A (es)
CA (1) CA2544693A1 (es)
CO (1) CO5690556A2 (es)
CR (1) CR8384A (es)
EC (1) ECSP066558A (es)
GT (1) GT200400232A (es)
IL (1) IL175389A0 (es)
NO (1) NO20062348L (es)
PA (1) PA8617101A1 (es)
PE (1) PE20050579A1 (es)
RU (1) RU2006120450A (es)
TW (1) TW200526583A (es)
WO (1) WO2005047257A2 (es)
ZA (1) ZA200603683B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8616901A1 (es) * 2003-11-10 2005-05-24 Wyeth Corp Metodos y composiciones para la inhibicion de selectina
EP1917245A1 (de) * 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
WO2008043075A2 (en) * 2006-10-05 2008-04-10 Wyeth Compositions for the treatment of scleritis
US20080255192A1 (en) * 2007-03-30 2008-10-16 Wyeth Methods and Compositions for Selectin Inhibition
WO2008121805A1 (en) 2007-03-30 2008-10-09 Wyeth Methods and compositions for selectin inhibition
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
US10295527B2 (en) 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
US11946927B2 (en) 2016-03-14 2024-04-02 Musidora Biotechnology Llc Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6083944A (en) * 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
WO1999029705A2 (en) 1997-12-08 1999-06-17 Glycomed Incorporated Sialyl lewis x and sialyl lewis a glycomimetics
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AU2002345796A1 (en) * 2001-06-26 2003-03-03 Beth Israel Deaconess Medical Center Compositions and methods for inhibiting platelet activation and thrombosis
EP1422782B1 (en) * 2001-07-06 2011-01-12 Nippon Kayaku Kabushiki Kaisha Photoelectric conversion element sensitized with methine dyes

Also Published As

Publication number Publication date
CA2544693A1 (en) 2005-05-26
EP1682511A2 (en) 2006-07-26
US20050101568A1 (en) 2005-05-12
ZA200603683B (en) 2008-05-28
ECSP066558A (es) 2006-10-17
US20090076077A1 (en) 2009-03-19
WO2005047257A2 (en) 2005-05-26
KR20060108666A (ko) 2006-10-18
CO5690556A2 (es) 2006-10-31
US7465799B2 (en) 2008-12-16
PE20050579A1 (es) 2005-09-08
WO2005047257A3 (en) 2005-07-07
TW200526583A (en) 2005-08-16
GT200400232A (es) 2005-09-14
NO20062348L (no) 2006-08-01
IL175389A0 (en) 2006-09-05
PA8617101A1 (es) 2006-09-22
JP2007510742A (ja) 2007-04-26
BRPI0416357A (pt) 2007-05-08
AU2004288800A1 (en) 2005-05-26
CN1902179A (zh) 2007-01-24
RU2006120450A (ru) 2007-12-27
CR8384A (es) 2006-12-07

Similar Documents

Publication Publication Date Title
AR074021A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
AR062050A1 (es) Derivados de amina utiles como agentes anti-cancerigenos
UY30603A1 (es) Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica
CO5180568A1 (es) Compuestos farmaceuticos, especialmente mutilinas, composiciones farmaceuticas que los contienen
UY28877A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida y composiciones
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
BR112012018865A2 (pt) naftiridinas substituídas e seu uso como inibidores de quinase syk
CO6241101A2 (es) Derivados de quinolina como inhibidores de la p13 quinasa
AR058554A1 (es) Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5.
CO5690557A2 (es) Metodos y composiciones para inhibicion de selectina
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR048315A1 (es) Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas.
AR050610A1 (es) Derivados de dihidropteridinona
AR044874A1 (es) Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
CO5690556A2 (es) Metodos y composiciones para la inhibicion de selectina
AR069804A1 (es) Agonistas del receptor glucocorticoide c20- c21 sustituido
PE20021004A1 (es) Derivados de piperidina como inhibidores de la ccr5
CO6150038A1 (es) Nuevos derivados de diosmetina su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR047981A1 (es) Inhibidores de caspasa y sus usos correspondientes
AR066605A1 (es) Derivados de heteroarilamida pirimidona
AR054266A1 (es) Indoles sustituidos con piperidina
AR047606A1 (es) 4-oxobenzonitrilos como moduladores de receptores de androgenos,composiciones farmaceuticas que los contienen y usos
AR055666A1 (es) Inhibidores inntr
AR054849A1 (es) Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas

Legal Events

Date Code Title Description
FB Suspension of granting procedure